A new study published in BMJ Global Health reveals a critical disconnect between WHO cancer medicine recommendations and the economic evidence available to support their implementation across African countries. Researchers examining 160 modifications to WHO cancer medicines between 2017 and 2023 found that 89% lacked robust economic data to justify adoption in resource-constrained settings.
The analysis, which assessed national essential medicines lists from 46 African low-income and lower middle-income countries, highlights a troubling pattern: while WHO recommendations guide medicine selection policies across the continent, most lack the cost and cost-effectiveness data essential for informed decision-making. When economic evidence did exist, researchers found it showed poor transferability to African healthcare contexts, limiting its practical utility for policymakers.
These findings underscore the need for more contextually relevant economic research to strengthen the evidence base for global health recommendations.
Was this article helpful?
